---
schema_version: "secwatch.filing_event.v1"
accession: "0001821586-24-000024"
form_type: "8-K"
ticker: "MLTX"
cik: "0001821586"
company_name: "MoonLake Immunotherapeutics"
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:52:13.932471+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MoonLake reports $519.8M cash; initiates Phase 3 VELA in HS, positive FDA/EMA feedback for PsA Phase 3

## Summary
- Q2 2024 cash, equivalents and short-term debt securities of $519.8M; cash runway to end-2026 unchanged.
- R&D expenses $23.7M (up from $13.0M prior quarter) driven by new trial initiations; G&A $6.9M.
- Phase 3 VELA program in hidradenitis suppurativa (HS) initiated; topline HiSCR75 primary endpoint expected mid-2025.
- Positive FDA and EMA feedback on regulatory path for Phase 3 IZAR program in psoriatic arthritis; topline results expected end-2026.
- Capital Markets Update on Sept 11; Phase 3 VELA TEEN in adolescent HS targeted for year-end 2024 initiation.

## SEC filing metadata
- accession: 0001821586-24-000024
- form_type: 8-K
- ticker: MLTX
- cik: 0001821586
- company_name: MoonLake Immunotherapeutics
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821586/000182158624000024/0001821586-24-000024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821586/000182158624000024/mnlk-20240807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001821586-24-000024
- JSON: https://secwatch.observer/filing/0001821586-24-000024.json
- Plain text: https://secwatch.observer/filing/0001821586-24-000024.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.